GLAND PHARMA
|
The Current P/E Ratio of GLAND PHARMA is 35.46.
| Share Price | ₹1,823.0 | Feb 27,2026 |
| Market Cap | ₹30,043.0 Cr | |
| Earnings-TTM | ₹847.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 35.46x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLAND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹30,043.0 Cr] as on Feb 27,2026
(/) Earnings [ ₹847.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 35.46x ]
Thus, for GLAND PHARMA , the investors are currently willing to pay 35.46 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLAND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLAND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of GLAND PHARMA
PE Ratio Performance Analysis for GLAND PHARMA
- GLAND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.71x.
- GLAND PHARMA 's operated at median p/e ratio of 39.27x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLAND PHARMA 's p/e ratio peaked in Mar2022 at 44.33x.
- GLAND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 26.75x.
How does GLAND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLAND PHARMA | 847.18 | 35.46 | 30,043.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.91 | 417,028.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 68.67 | 170,237.0 |
| CIPLA LTD | 4,544.70 | 23.95 | 108,861.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 64.61 | 146,801.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.50 | 107,435.0 |
| MANKIND PHARMA LTD | 1,796.65 | 51.64 | 92,784.1 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.81 | 92,825.1 |
| LUPIN LTD | 4,669.18 | 22.53 | 105,182.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 20.19 | 70,947.8 |
| ABBOTT INDIA LTD | 1,524.13 | 36.94 | 56,300.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLAND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.81x |
| Max industry PE | 68.67x |
| Median industry PE | 35.46x |
| Average industry PE | 36.38x |
You may also like the below Video Courses